Amgen (AMGN) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2301201/amgen-amgn-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2301201
Jul 12, 2024 - Amgen (AMGN) reachead $330.83 at the closing of the latest trading day, reflecting a +1.77% change compared to its last close.
0
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
https://www.zacks.com/stock/news/2300219/novo-nordisk-nvo-soars-38-ytd-how-should-you-play-the-stock?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2300219
Jul 11, 2024 - Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
0
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
https://www.fool.com/investing/2024/07/09/can-eli-lilly-surpass-1000-this-year/?source=iedfolrf0000001
Jul 09, 2024 - This pharma company is posting double-digit revenue growth.
0
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
https://www.zacks.com/stock/news/2296877/nvo-lly-slip-after-study-links-obesity-drug-use-to-vision-loss?cid=CS-ZC-FT-analyst_blog|industry_focus-2296877
Jul 04, 2024 - A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
0
Take the Zacks Approach to Beat the Markets: NVIDIA, Seagate, Amkor in Focus
https://www.zacks.com/stock/news/2295818/take-the-zacks-approach-to-beat-the-markets-nvidia-seagate-amkor-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2295818
Jul 01, 2024 - Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
0
1 Dividend Growth Stock to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/06/29/1-dividend-growth-stock-to-buy-hold-for-10-years/?source=iedfolrf0000001
Jun 29, 2024 - This company's payouts look safe.
0
Top Stock Reports for Chevron, Amgen & Philip Morris
https://www.zacks.com/commentary/2292698/top-stock-reports-for-chevron-amgen-philip-morris?cid=CS-ZC-FT-research_daily-2292698
Jun 25, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and Philip Morris International Inc. (PM), as well as two micro-cap stocks Hurco Companies, Inc. (HURC) and Perma-Pipe International Holdings, Inc. (PPIH).
0
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
https://www.zacks.com/stock/news/2291052/biotech-stock-roundup-itci-up-on-study-data-zntl-ovid-down-on-updates-more-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2291052
Jun 20, 2024 - Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
0
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
https://www.zacks.com/stock/news/2289221/amgen-s-amgn-blincyto-gets-fda-nod-for-consolidation-treatment?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2289221
Jun 17, 2024 - Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
0
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
https://www.zacks.com/stock/news/2287309/viridian-vrdn-up-10-on-clinical-updates-for-eye-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2287309
Jun 12, 2024 - Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026
0